Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -18.03
- Piotroski Score 2.00
- Grade N/A
- Symbol (BENF)
- Company Beneficient
- Price $0.82
- Changes Percentage (-9.11%)
- Change -$0.08
- Day Low $0.72
- Day High $0.88
- Year High $51.12
Beneficient, a technology-enabled financial service company, provides liquidity solutions to participants in the alternative asset industry. It operates AltAccess platform, which provides liquidity, custody, and investment analytics solutions, including AltLiquidity, an online tool that helps to find liquidity solutions for its alternative assets on a cybersecure platform; AltQuote, a quote tool for alternative assets; AltAccess, a secure platform for end-to-end alternative asset transactions; AltCustody to digitize and track its alternative assets; AltData, an investment analytics for its alternative asset data in one place; and AltTrading, a trading solution. The company serves mid-to-high net worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. The company is based in Dallas, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$598.79
- Trailing P/E Ratio -0.01
- Forward P/E Ratio -0.01
- P/E Growth -0.01
- Net Income $-2,657,392,000
Income Statement
Quarterly
Annual
Latest News of BENF
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
The newly approved schizophrenia drug, Cobenfy, offers a novel treatment approach targeting cholinergic receptors. Despite its potential benefits, challenges like high cost and insurance coverage rest...
By Forbes | 2 weeks ago -
Grudges aren't just great fun - they might have an evolutionary benfit. Ask a crow | Zoe Williams
Resentments exist even in the animal kingdom, as seen with crows holding grudges. Research suggests grudges may have an evolutionary advantage. Forgiveness is linked to better health. Multigenerationa...
By The Guardian | 2 weeks ago -
Beneficient (BENF) Stock Price, News, Quote & History - Yahoo Finance
Beneficient, a financial services holding company, restructured $126 million of preferred equity as non-redeemable through its subsidiary Beneficient Company Holdings, L.P., approved by the founders....
By Yahoo! Finance | 1 month ago
